Journal article
Authors list: Goedde, A.; Mueller-Ladner, U.
Publication year: 2006
Pages: 1263-1268
Journal: Der Internist
Volume number: 47
Issue number: 12
ISSN: 0020-9554
eISSN: 1432-1289
DOI Link: https://doi.org/10.1007/s00108-006-1754-0
Publisher: Springer
Abstract:
Arthralgia is one of the most common complaints in Western society. The classification of joint diseases with respect to genesis is crucial for the determination of adequate treatment. For inflammatory arthropathies, treatment options have expanded significantly over the last decade. This review summarizes the current treatment of psoriatic arthritis and Reiter's disease, both belonging to the spectrum of seronegative spondyloarthropathies. Regardless of our increasing knowledge of chondrogenesis, the treatment of osteoarthritis is still more or less symptomatic. Premature age of onset and the atypical joint distribution of osteoarthritis should bring metabolic diseases, for example hemochromatosis, into consideration.
Citation Styles
Harvard Citation style: Goedde, A. and Mueller-Ladner, U. (2006) Therapy for secondary arthropathies.: From psoriasis and Reiter's disease to hemochromatosis, Der Internist, 47(12), pp. 1263-1268. https://doi.org/10.1007/s00108-006-1754-0
APA Citation style: Goedde, A., & Mueller-Ladner, U. (2006). Therapy for secondary arthropathies.: From psoriasis and Reiter's disease to hemochromatosis. Der Internist. 47(12), 1263-1268. https://doi.org/10.1007/s00108-006-1754-0
Keywords
ARTHROPATHY; CLINICAL-TRIAL; CONTROLLED TRIAL; CYCLOSPORINE; DOUBLE-BLIND; HEMOCHROMATOSIS; METHOTREXATE THERAPY; PLACEBO; Psoriatic arthritis; REACTIVE ARTHRITIS; spondyloarthropathy; SULFASALAZINE